160 related articles for article (PubMed ID: 37855989)
1. Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators.
Volta F; La Monica S; Leonetti A; Gnetti L; Bonelli M; Cavazzoni A; Fumarola C; Galetti M; Eltayeb K; Minari R; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2023 Nov; 18(6):953-964. PubMed ID: 37855989
[TBL] [Abstract][Full Text] [Related]
2. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
[TBL] [Abstract][Full Text] [Related]
3. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.
Osoegawa A; Takumi Y; Hashimoto T; Nakatsuji S; Hori M; Sakai M; Karashima T; Abe M; Miyawaki M; Sugio K
Invest New Drugs; 2023 Apr; 41(2):183-192. PubMed ID: 36790603
[TBL] [Abstract][Full Text] [Related]
5. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
6. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
7. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
[TBL] [Abstract][Full Text] [Related]
8. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
[TBL] [Abstract][Full Text] [Related]
9. Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer.
Cai X; Miao J; Sun R; Wang S; Molina-Vila MA; Chaib I; Rosell R; Cao P
Pharmacol Res; 2021 Aug; 170():105701. PubMed ID: 34087353
[TBL] [Abstract][Full Text] [Related]
10. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
Li XF; Shen WZ; Jin X; Ren P; Zhang J
Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
[TBL] [Abstract][Full Text] [Related]
11. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
12. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
13. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer.
Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
Thorac Cancer; 2021 Jun; 12(11):1708-1715. PubMed ID: 33943009
[TBL] [Abstract][Full Text] [Related]
14. Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.
La Monica S; Minari R; Cretella D; Bonelli M; Fumarola C; Cavazzoni A; Galetti M; Digiacomo G; Riccardi F; Petronini PG; Tiseo M; Alfieri R
Target Oncol; 2019 Oct; 14(5):619-626. PubMed ID: 31502118
[TBL] [Abstract][Full Text] [Related]
15. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
16. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
17. EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Nanamiya R; Saito-Koyama R; Miki Y; Inoue C; Asavasupreechar T; Abe J; Sato I; Sasano H
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445227
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
19. Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.
Takahashi H; Sakakibara-Konishi J; Furuta M; Shoji T; Tsuji K; Morinaga D; Kikuchi E; Kikuchi J; Noguchi T; Hatanaka KC; Hatanaka Y; Shinagawa N; Konno S
Cancer Sci; 2023 Apr; 114(4):1635-1650. PubMed ID: 36411521
[TBL] [Abstract][Full Text] [Related]
20. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]